<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527930</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-BR-0703, H-0706-009-209</org_study_id>
    <nct_id>NCT00527930</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer</brief_title>
  <acronym>TORCH</acronym>
  <official_title>Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial of oxaliplatin in combination with S-1(SOX) in patients with recurrent or&#xD;
      metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline and&#xD;
      taxane&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to find out the efficacy and safety profile of TS-1 with&#xD;
      oxaliplatin in previously anthracycline and taxane pretreated patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>TTP, OS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- To determine the time to progression - To determine the response duration - To determine the overall survival - To determine toxicities - To determine the pharmacogenomic predictor (association study)</measure>
    <time_frame>PFS, OS</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">87</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1 and Eloxatin</intervention_name>
    <description>S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week&#xD;
Number of Cycles: until progression or unacceptable toxicity</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  M/F age ≥ 18&#xD;
&#xD;
          -  Metastatic(TxNxM1) or inoperable locally recurrent breast cancer(rT4NxM0) after taxane&#xD;
             &amp; anthracycline therapy&#xD;
&#xD;
          -  Measurable disease (RECIST) : A patient with at least one measurable lesion of which&#xD;
             the diameter is confirmed to be 10mm in spiral CT or multidetector CT (MD CT), or 20&#xD;
             mm or longer in conventional CT&#xD;
&#xD;
          -  No prior treatment with S-1, capecitabine, platinum In metastatic setting&#xD;
&#xD;
          -  Must have received an anthracycline and taxane in adj. or metastatic settings&#xD;
             (concurrent, sequential, or combined with other drugs)&#xD;
&#xD;
          -  For taxanes (Paclitaxel (P) / Docetaxel (D))&#xD;
&#xD;
               1. Must have progressed while or after receiving P or D (Patients who relapse within&#xD;
                  12 months of completing adjuvant chemotherapy containing an anthracycline and a&#xD;
                  taxane, do not require prior chemotherapy for metastatic disease)&#xD;
&#xD;
               2. Only 1 adjuvant regimen permitted (neoadjuvant immediately followed by surgery&#xD;
                  and immediately followed by adj. is permitted)&#xD;
&#xD;
          -  For anthracyclines&#xD;
&#xD;
               1. Progressed while on anthracycline treatment, with or without initial response or&#xD;
&#xD;
               2. Have received an adequate course of anthracyclines defined as follows:&#xD;
&#xD;
               1. Adj.: Must have received a standard regimen (doxorubicin ≥ 240 mg/m2 or ≥ 360&#xD;
                  mg/m2 epirubicin or equivalent)&#xD;
&#xD;
               2. Metastatic: Must have received a standard regimen(doxorubicin ≥300mg/m2 or&#xD;
                  equivalent)&#xD;
&#xD;
          -  Not candidate for Herceptin&#xD;
&#xD;
          -  ECOG PS ≤ 2&#xD;
&#xD;
          -  Completion of all prior chemotherapy ≥ 3 wks prior to enrol&#xD;
&#xD;
          -  Completion of hormonal therapy 2 wks prior to enroll&#xD;
&#xD;
          -  Resolution of all clinically significant toxic effects (excluding alopecia and sensory&#xD;
             neuropathies) of any prior surgery or therapy to grade ≤ 1 (NCI CTCAE 3.0), for&#xD;
             peripheral neuropathy grade ≤ 2 (NCI CTCAE 3.0), or to within the limits listed in the&#xD;
             specific inclusion/exclusion criteria&#xD;
&#xD;
          -  A patient with the willingness to comply with the study protocol during the study&#xD;
             period and capable of complying with it.&#xD;
&#xD;
          -  Informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WOCBP(woman of child bearing potential) unwilling to use acceptable method to avoid&#xD;
             pregnancy&#xD;
&#xD;
          -  Breast feeding or pregnant women&#xD;
&#xD;
          -  Patients with Hx of symptomatic brain or leptomeningeal involvement (eligible if&#xD;
             asymptomatic 2weeks after proper radiation therapy)&#xD;
&#xD;
          -  ≥grade 3 neuropathy currently&#xD;
&#xD;
          -  Hx of second malignancy except adequately treated basal or squamous skin ca or CIS of&#xD;
             cervix. Adequately treated contralateral breast ca with DF &gt;5 yrs prior to this study&#xD;
             is permitted&#xD;
&#xD;
          -  MI, unstable angina, CABG, clinically significant arrhythmia within 6 mo&#xD;
&#xD;
          -  Hx of inflammatory bowel disease or chronic diarrhea,&#xD;
&#xD;
          -  ANC &lt; 1500, Plt &lt; 100K, Hb &lt;9.0&#xD;
&#xD;
          -  Ccr &lt; 60 ml/min or creatinine &gt;1.5&#xD;
&#xD;
          -  Bil &gt; 1.5 x UNL, AST/ALT ≥ 2.5xUNL if hepatic meta + &gt; 5xUNL)&#xD;
&#xD;
          -  History of hypersensitivity to 5-FU, platinum, or to compounds with similar chemical&#xD;
             structures&#xD;
&#xD;
          -  More than 3 prior chemotherapy for metastatic or recurrent disease or prior treatment&#xD;
             with S-1, capecitabine or any platinum analogs in metastatic setting (5-FU combine&#xD;
             with other agent in metastatic setting is allowed_ ex) CMF, FAC)&#xD;
&#xD;
          -  Her2(+) pts who are candidates for Herceptin&#xD;
&#xD;
          -  prior surgery within 4 week&#xD;
&#xD;
          -  participate in other clinical trials within 4 week&#xD;
&#xD;
          -  prior radiation therapy within 2 week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seock-Ah Im, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.kcsg.org/</url>
    <description>Korean Cancer Study Group</description>
  </link>
  <link>
    <url>http://cris.snuh.org</url>
    <description>Seoul National University Hospital Clinical Trial Center</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>September 8, 2007</study_first_submitted>
  <study_first_submitted_qc>September 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seock-Ah Im</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>S1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

